Davide Dettori, CEO of Health Triage, is leading the development of AI for oncological diagnostics. From virtual biopsy to precision prevention, his goal is to bring validated technologies into global clinical practice.
Bringing artificial intelligence into clinical practice is no longer a promise — it is a concrete challenge that requires scientific rigour, multidisciplinary integration and industrial vision. In this interview, Davide Dettori tells the story of Health Triage: from its origins to the development of advanced diagnostic solutions, to the ambition of redefining oncological prevention on a global scale, making it more precise, accessible and truly applicable in everyday medical practice.
Q: Where does Health Triage come from, and what is your mission?
A: Health Triage was born from a very concrete vision: using the power of artificial intelligence to improve oncological diagnostics. We want to make prevention more precise, less invasive and truly accessible. We started with the two cancers with the greatest social and clinical impact — breast and prostate — and set ourselves a clear goal: to change the paradigm of preventive medicine.
Q: What sets you apart from a simple medical software house?
A: We are a clinical enabler, not a tech company dressed up as a medical one. We build technologies that integrate AI, clinical practice, regulatory compliance and scientific validation into a single, cohesive process. BreastNegative and PROSTATE V-Bio are not just tools — they are medical devices designed to be adopted in everyday clinical practice. This is what makes us global first movers in areas such as virtual biopsy.
Q: How do you concretely work to turn this vision into reality?
A: We have a truly interdisciplinary operating model: our team brings together physicians, engineers, medical physicists, data scientists, regulatory experts and software developers. There are no silos — everything is built through integrated design from the very beginning. Every technology we develop must pass rigorous internal testing. We always assess the needs and who will actually use it in practice, and only then do we move on to clinical trials and hospital deployment with all the necessary certifications.
Q: Health Triage has a global outlook. Who are your strategic partners, and where do you want to go?
A: Today we work with organisations such as Cancer Research Horizons and the Royal Surrey in the United Kingdom, as well as numerous centres across Italy. We also operate under the scientific supervision of GISMa and SIU. We are in dialogue with US centres and with the FDA to extend our medical devices beyond Europe. The goal is clear: to bring rigorously controlled, evidence-based artificial intelligence to the centre of global clinical medicine — with reliable, certified and fully interoperable tools.
Q: What is your highest ambition?
A: It is not enough for us to demonstrate that artificial intelligence can become a clinical standard. For us, that is just the starting point. The true potential of AI lies in everything that surrounds the initial diagnosis — what we call the upsides. Take Virtual Biopsy as an example: the volume of data we process can have an enormous impact on treatments such as radiotherapy, pharmacological therapies or surgery. And if we then begin integrating molecular data as well, we move to an entirely different level. We are not talking about futuristic promises, but about concrete, regulated, validated clinical practice that is useful every day. We like to imagine BreastNegative present in every screening programme in the world. And an algorithm like PROSTATE V-Bio allowing millions of men to avoid unnecessary biopsies. This change only makes sense if it actually happens — in the clinic, with real benefits for patients. Because we are not just building software. We want to transform preventive medicine into precision medicine.
